---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Heterogeneity of treatment effect"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Heterogeneity of treatment effect. Topics: MuSK antibody-positive disease: response to conventional therapies, MuSK antibody-positive disease: complement independence and thymectomy, Rituximab response by antibody status, Inebilizumab effect by antibody status, and 5 further topics. 9 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### MuSK antibody-positive disease: response to conventional therapies

> “Many patients with MuSK-MG respond poorly to ChEIs, and conventional pyridostigmine doses frequently induce side effects.”
> “Patients with MuSK-MG appear to respond well to corticosteroids and to many steroid-sparing IS agents. They tend to remain dependent on prednisone despite concomitant treatment with steroid-sparing agents.”
> “MuSK-MG responds well to PLEX, while IVIg seems to be less effective.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.3-2"></a>

### MuSK antibody-positive disease: complement independence and thymectomy

> “The observation of predominant IgG4 antibodies in patients with MuSK MG is indicative of immune response that corresponds with the IgG4 autoimmune diseases ( 9 ) and the antiinflammatory properties of the IgG4 that include the inability to activate complement.”
> “The thymus is normal ( 116 ), and thymectomy does not benefit patients with MuSK with MG”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.3-3"></a>

### Rituximab response by antibody status

> “A retrospective combined analysis of previously published case reports of 169 patients between January 2000 and August 2015 reported that 72% of MuSK-Ab + MG and 30% of AChR-Ab+ MG patients treated with RTX achieved MM status or better.”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.3-4"></a>

### Inebilizumab effect by antibody status

| Week 26 outcome | Overall population | Anti-AChR antibody positive | Anti-MuSK antibody positive |
| --- | --- | --- | --- |
| MG-ADL difference from placebo | “-1.9” | “-1.8” | “-2.2” |
| MG-ADL p-value | “<0.0001” | “0.0015” | “0.0297” |
| QMG difference from placebo | “-2.5” | “-2.5” | “-2.3” |
| QMG p-value | “0.0002” | “0.0011” | “NS” |

Source: [Uplizna prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761142s004lbl.pdf)

<a id="topic-2.2.2.3-5"></a>

### Seronegative disease: efgartigimod in anti-AChR antibody-negative adults

> “The efficacy of VYVGART for the treatment of adult patients with gMG who are anti-AChR antibody negative was established in an 8-week, randomized double-blind, placebo-controlled study (Study 2 Part A; NCT06298552).”
> “In Study 2 Part A, a total of 119 patients were randomized 1:1 to receive once-weekly infusions for 4 weeks of either VYVGART 10 mg/kg (1,200 mg for those weighing 120 kg or more) (n=58) or placebo (n=61).”
> “Sixty-one percent of patients were triple seronegative (i.e., anti-AChR, anti-MuSK, and anti-low- density lipoprotein receptor-related protein 4 [LRP4] antibodies negative). Thirty-four percent of patients were positive for anti-MuSK antibodies, and 5% of patients were positive for anti-LRP4 antibodies.”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.2.2.3-6"></a>

### Antibody subgroups enrolled in FcRn blocker trials

> “The majority of patients, 89.5% (n=179) were positive for AChR antibodies and 10.5% (n=21) were positive for MuSK antibodies.”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

> “Eighty-eight percent (n=134) of patients were positive for AChR antibodies and 10% (n=16) were positive for MuSK antibodies.”

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-2.2.2.3-7"></a>

### Ocular versus generalized disease

> “In 20% of MG patients, the muscle weakness remains confined to the extraocular muscles”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “The efficacy of IVIg is less certain in milder MG or in ocular MG.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “Corticosteroids should be used as the initial IS agent in ocular MG. Steroid-sparing IS agents may be needed when corticosteroids alone are ineffective, contraindicated, or not tolerated”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.3-8"></a>

### Age and thymectomy benefit

> “In a post hoc analysis, neither the prednisone dose nor QMG scores were significantly different between the 2 treatment groups in patients 50 years or older.”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.3-9"></a>

### Claseprubart: baseline QMG subgroup in the phase 2 trial

> “A subgroup analysis of patients enrolled in the MaGic trial with a QMG score ≥10 at baseline which demonstrated an increase in MG-ADL treatment effect for 300mg/2mL Q2W to a 3-point difference from placebo”

Source: [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
